The dark side of antiviral T cell responses
Nat Neurosci
.
2019 Aug;22(8):1199-1200.
doi: 10.1038/s41593-019-0454-8.
Authors
Karen Krukowski
1
2
,
Susanna Rosi
3
4
5
6
7
Affiliations
1
Department of Physical Therapy and Rehabilitation Science, University of California, San Francisco, CA, USA.
2
Brain and Spinal Injury Center, University of California, San Francisco, San Francisco, CA, USA.
3
Department of Physical Therapy and Rehabilitation Science, University of California, San Francisco, CA, USA. susanna.rosi@ucsf.edu.
4
Brain and Spinal Injury Center, University of California, San Francisco, San Francisco, CA, USA. susanna.rosi@ucsf.edu.
5
Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA. susanna.rosi@ucsf.edu.
6
Weill Institute for Neuroscience, University of California San Francisco, San Francisco, CA, USA. susanna.rosi@ucsf.edu.
7
Kavli Institute of Fundamental Neuroscience, University of California, San Francisco, San Francisco, CA, USA. susanna.rosi@ucsf.edu.
PMID:
31346293
DOI:
10.1038/s41593-019-0454-8
No abstract available
Publication types
Comment
MeSH terms
Antiviral Agents*
Cognitive Dysfunction*
Flavivirus*
Humans
Microglia
T-Lymphocytes
Substances
Antiviral Agents
Grants and funding
R01 AG056770/AG/NIA NIH HHS/United States
R01 CA133216/CA/NCI NIH HHS/United States
R01 CA213441/CA/NCI NIH HHS/United States